ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v9i2.237ppharm-342Research ArticleНОВЫЕ МЕДИЦИНСКИЕ ТЕХНОЛОГИИNEW TECHNOLOGIES IN MEDICINEНЕПРЯМЫЕ СРАВНЕНИЯ В ОЦЕНКЕ МЕДИЦИНСКИХ ТЕХНОЛОГИЙINDIRECT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENTГоряйновС. В.GoryajnovS. V.
младший научный сотрудник НИЛ доказательной медицины и клинической экспертизы НИИ клинико-экономической экспертизы и фармакоэкономики РНИМУ им. Н.И. Пирогова
niikeef@yandex.ruРеброваО. Ю.RebrovaO. Yu.neonatepearl@yandex.ruРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова, МоскваРоссияN.I. Pirogov Russian National Research Medical University, MoscowRussian Federation20120404201292Педиатрическая фармакология69Copyright © Горяйнов С.В., Реброва О.Ю., 20122012Горяйнов С.В., Реброва О.Ю.Goryajnov S.V., Rebrova O.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/342непрямые сравненияоценка медицинских технологийгепатит Спегилированные интерфероныindirect treatment comparisonhealth technology assessmenthepatitis Cpegylated interferonsReferencesBucher H.C., Gordon H.G., Lauren E.G., Walter S.D. The results of direct and indirect treatment comparisons in metaanalysis of randomized controlled trials. J ClinEpidemiol. 1997; 50 (6): 683-91Bucher H.C., Gordon H.G., Lauren E.G., Walter S.D. The results of direct and indirect treatment comparisons in metaanalysis of randomized controlled trials. J ClinEpidemiol. 1997; 50 (6): 683-91Jansen J.P., Fleurence R., Devine B. et al. Interpreting indirect treatment comparisons and network metaanalysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices.Part 1.Value In Health. 2011; 14: 417-428.Jansen J.P., Fleurence R., Devine B. et al. Interpreting indirect treatment comparisons and network metaanalysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices.Part 1.Value In Health. 2011; 14: 417-428.Song F., Altman D.G., Glenny A.M. et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta analyses. BMJ.2003; 1: 326.Song F., Altman D.G., Glenny A.M. et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta analyses. BMJ.2003; 1: 326.Hoaglin D.C., Hawkins N., Jansen J.P. et al. Conducting indirect-treatment-comparison and networkmetaanalysisstudies: report of the ISPOR task force on indirect treatment comparisons good research practices.Part 2.Value In Health. 2011; 14: 429-437.Hoaglin D.C., Hawkins N., Jansen J.P. et al. Conducting indirect-treatment-comparison and networkmetaanalysisstudies: report of the ISPOR task force on indirect treatment comparisons good research practices.Part 2.Value In Health. 2011; 14: 429-437.Song F., Harvey I., Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J ClinEpidemiol. 2008; 61 (5): 455-463.Song F., Harvey I., Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J ClinEpidemiol. 2008; 61 (5): 455-463.Rumi M.G., Agemo A., Prati G.M. et al. Randomized study of peginterferon-?2a plus ribavirin vspeginterferon-?2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010; 138: 108-115.Rumi M.G., Agemo A., Prati G.M. et al. Randomized study of peginterferon-?2a plus ribavirin vspeginterferon-?2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010; 138: 108-115.Ascione A., Luca M.D., Tartaglione M.T. et al. Peginterferonalfa-2a plus ribavirin ismore effective than peginterferonalfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010; 138: 116-122.Ascione A., Luca M.D., Tartaglione M.T. et al. Peginterferonalfa-2a plus ribavirin ismore effective than peginterferonalfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010; 138: 116-122.McHutchison J.G., Lawitz E.J., Shiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009; 361 (6): 580-593.McHutchison J.G., Lawitz E.J., Shiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009; 361 (6): 580-593.Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358 (9286): 958-965.Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358 (9286): 958-965.Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. NEnglJMed. 2002; 347 (13): 975-982.Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. NEnglJMed. 2002; 347 (13): 975-982.
The authors declare that there are no conflicts of interest present.